GE Healthcare
gehealthcare.comTotal trials
166
Active
16
Phase 3
21
Total enrollment
28,681
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 7 of 7 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| 18F Fluoroestradiol Radiopharmaceutical with PET/CT | — | — | — | — | 2 | ||
| Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL | — | — | — | — | — | 1 | |
| Gadobutrol | — | — | — | — | — | 1 | |
| GEH300079 | — | — | — | — | — | 1 | |
| Regadenoson | — | — | — | — | — | 1 | |
| GEH200520 Injection / GEH200521 (18F) Injection - Part A | — | — | — | — | — | 1 | |
| GEH200520 Injection / GEH200521 (18F) Injection - Part B | — | — | — | — | — | 1 |
Next readouts
- 2025-04-18
- 2026-12
- 2027-11-30
- 2029-03-10
- 2029-06
Top conditions
- Breast Cancer15
- Coronary Artery Disease11
- Blood Pressure6
- Healthy6
- Alzheimer's Disease4
- Coronary Artery Disease (CAD)4
- Traumatic Brain Injury4
- Tumors, Breast3
Frequently asked questions about GE Healthcare
- How many clinical trials does GE Healthcare have on ClinicalTrials.gov?
- GE Healthcare is listed as the lead sponsor on 166 clinical trials in ClinicalTrials.gov, 16 of which are currently active (recruiting, enrolling, or ongoing).
- How many of GE Healthcare's trials are in Phase 3?
- 21 of GE Healthcare's trials are in Phase 3, spread across 7 active drug programs.
- What therapeutic areas does GE Healthcare focus on?
- GE Healthcare's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Coronary Artery Disease, Blood Pressure, Healthy, Alzheimer's Disease.
- When are GE Healthcare's next clinical trial readouts?
- GE Healthcare has 5 upcoming primary-completion readouts tracked here; the soonest is “Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer”, expected around 2025-04-18.